Publications by authors named "Miho Sakumura"

Article Synopsis
  • Pembrolizumab, nivolumab, and the combination therapies have emerged as first-line treatments for advanced esophageal cancer, although their efficacy on primary tumors was previously unclear.
  • In a study of 23 patients experiencing esophageal dysphagia, significant improvement in swallowing was noted in 82.6%, with a median time to improvement of about 26 days.
  • While 10 patients experienced immune-related adverse events, the treatments provided high response rates and prolonged survival, indicating promising effectiveness against primary tumors.
View Article and Find Full Text PDF
Article Synopsis
  • No reliable marker for predicting peritoneal metastasis during chemotherapy for advanced gastric cancer (AGC) currently exists, which complicates treatment effectiveness.
  • A study examining 73 AGC patients receiving TAX/RAM therapy found that elevated serum CA125 levels were significantly associated with the presence of peritoneal metastasis, with 80.6% of patients showing increased CA125 levels having this condition.
  • The study concluded that monitoring CA125 kinetics can serve as an early indicator of peritoneal metastasis progress in patients undergoing this chemotherapy regimen.
View Article and Find Full Text PDF
Article Synopsis
  • * A retrospective study from December 2021 to June 2023 analyzed 106 AGC patients, focusing on those with severe peritoneal metastasis who received nivolumab plus mFOLFOX6, finding that 19.8% of patients had severe cases.
  • * Results showed a median progression-free survival of 7.4 months and median overall survival of 10.7 months, with notable improvements in symptoms for a number of patients; however, some experienced significant
View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors (ICIs) show varying effectiveness depending on the metastatic site in gastric cancer (GC), influencing patient survival outcomes.
  • In a study of 148 GC patients treated with ICIs, those with non-systemic progression lived significantly longer than those with systemic progression, indicating different responses based on tumor growth patterns.
  • Liver metastasis was found to be particularly detrimental, correlating with lower CD8+ T-cell density and worse survival, suggesting that it may predict systemic progression in GC patients receiving ICIs.
View Article and Find Full Text PDF

Background: Chronic constipation is prevalent and involves both colon sensitivity and various changes in intestinal bacteria, particularly mucosa-associated microflora. Here we examined regulatory mechanisms of TRPV4 expression by co-culturing colon epithelial cell lines with intestinal bacteria and their derivatives. We also investigated TRPV4 expression in colon epithelium from patients with constipation.

View Article and Find Full Text PDF
Article Synopsis
  • Third-line chemotherapy may enhance survival in advanced gastric cancer patients, prompting a study to determine factors affecting eligibility for clinical trials.
  • Researchers analyzed 335 patients who received first-line chemotherapy, categorizing them into eligible (40.6%) and ineligible (59.4%) groups, with survival outcomes showing a significant difference (16.8 months vs. 9.3 months).
  • Key risk factors for third-line chemotherapy eligibility included being ineligible for clinical trials, number of metastatic sites, low albumin levels, and poor response to first-line treatment, but responders still showed a better prognosis even when they were ineligible for trials.
View Article and Find Full Text PDF

Background/aim: Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis. Chemotherapy should be selected in consideration of hematological toxicities because these patients are at high risk of hemorrhagic complications. The leucovorin, fluorouracil, and oxaliplatin (FOLFOX) regimen is an effective and less toxic regimen for patients with AGC and poor performance status.

View Article and Find Full Text PDF

Chemotherapy-induced diarrhea (CID) is a common, severe side effect of chemotherapy, immunotherapy, and targeted therapy. Because patients are more prone to continuing chemotherapy if they do not suffer from CID, appropriate diagnosis and monitoring of this disease are essential. However, suitable monitoring methods are yet to be developed.

View Article and Find Full Text PDF

We herein report a 73-year-old woman with BRAF V600E-mutated colon cancer treated with encorafenib plus cetuximab with binimetinib as standard salvage therapy for patients with advanced colorectal cancer. She developed bilateral serous retinal detachment the next day, and the regimen was discontinued, resulting in complete resolution by the third day. Doublet therapy without binimetinib was initiated along with a weekly ophthalmologic examination for 10 weeks without recurrence of retinal detachment.

View Article and Find Full Text PDF

Background: Constitutional mismatch repair deficiency (CMMRD) is an extremely rare autosomal recessive hereditary disease characterized by the absence of mismatch repair gene activity from birth, which results in brain tumors, colonic polyposis, gastrointestinal cancers, and lymphomas later in life. An aggressive approach, including colectomy or proctocolectomy, is recommended for the treatment of colorectal cancer. Additionally, partial colectomy with subsequent endoscopic surveillance may be an alternative strategy due to poor patient's condition, although there is no evidence of surveillance endoscopy after partial colectomy for CMMRD.

View Article and Find Full Text PDF
Article Synopsis
  • Diarrhea is a common side effect of fluoropyrimidine chemotherapy, but this study investigates the occurrence and risk factors of more severe, complicated diarrhea and small bowel damage in patients.
  • In a review of 536 patients with advanced gastrointestinal cancer, 6% experienced complicated diarrhea, often accompanied by symptoms like cramping, vomiting, or sepsis.
  • The study found that most patients with complicated diarrhea showed small intestinal damage, and taking oral fluoropyrimidine increased the risk of these complications.
View Article and Find Full Text PDF

Although nivolumab was previously reported to cause immune-related interstitial lung diseases (ILD), the detailed characteristics of ILD in gastric cancer are not fully understood. We herein present a rare case of a 66-year-old male with advanced gastric cancer who experienced acute-onset high-grade fever and dyspnea and diagnosed with early-onset ILD during the first cycle of nivolumab. Computed tomography revealed patchy infiltrative shadows and ground-glass opacities.

View Article and Find Full Text PDF

Hepatic sinusoidal obstruction syndrome (SOS), a serious complication that mainly occurs after hematopoietic-stem cell transplantation (HSCT), is caused by damage to the sinusoidal endothelial cells after the obstruction of the sinusoid. Recently, hepatic SOS was reported to occur after non-HSCT chemotherapies. This report describes a patient who experienced hepatic SOS after non-HSCT chemotherapy for non-Hodgkin lymphoma.

View Article and Find Full Text PDF